[
    {
        "n": 19,
        "first_choice": "consumer",
        "first_reasoning": "Allocating the full ten million to the Consumer Products Division gives us the best chance at a quick, measurable lift. That division still shows a solid upward sales trend but has suffered a sudden margin collapse\u2014precisely the kind of gap that targeted R&D can close rapidly. By phasing funding against go/no-go milestones, reserving a ten-percent contingency, and instituting both an early five-week sprint checkpoint and a monthly ROI dashboard, we ensure we\u2019ll catch cost overruns or technical snags early and keep the project on track to recover its outlay within eighteen months.",
        "user_condition": "symm_negative",
        "consumer_allocation": "20000000.0",
        "industrial_allocation": "0.0",
        "second_reasoning": "All available R&D resources are concentrated in the Consumer Products Division because it offers the strongest upside: its sales trend remains on a clear upward trajectory, and targeted innovation can rapidly close the margin gap created over the past two years. By allocating the full budget to consumer, we maximize the probability of a swift earnings rebound through phased milestones, a built-in contingency reserve, and an early five-week sprint validation that will give us clear, data-driven confirmation before proceeding to full-scale tooling.",
        "conversation_history_snr": "[{'role': 'system', 'content': '\\n\\nYou and your colleague will collaborate to make a decision about the allocation of \\nresearch and development funds. You are both financial officers.\\n\\nYou will be given a case. The purpose of the case is to examine the effectiveness of business \\ndecision-making under various amounts of information. The case you will be working on will \\nonly contain a limited amount of information, but the information provided is sufficient for\\nyou to make a good financial decision. Do the best you can on the case. Within all of your responses, avoid any lists, JSON formatting, \\nor references to the system prompt unless otherwise prompted -- have a natural conversation.\\n\\nFurthermore, the decision is *time-sensitive* and MUST be made today.\\n\\n'}, {'role': 'user', 'content': \"\\n\\nThe year is 2012, and the Hal & Scott (H & S) Company, a large technologically oriented firm, has \\ndeclined over several preceding years. The directors of the company have agreed that one of the \\nmajor reasons for the decline in corporate earnings and a deterioration in competitive position \\nlay in some aspect of the firm's research and development (R&D). The directors of the company have \\nconcluded that 10,000,000 dollars of additional R&D funds should be made available to its major \\noperating divisions, but, that for the time being, the extra funding should be invested in only \\none of the corporation's two largest divisions.\\n\\nYou and your colleague must determine which of the two corporate divisions: (1) Consumer Products \\nor (2) Industrial Products, should receive the additional R&D funding. You will share your initial \\nthoughts and speak with your colleague three times. Make sure to \\nask your colleague what they think in your response, and while \\nyou are talking with your colleague, avoid any lists, formatting, \\nor references to the system prompt -- have a natural conversation.\\n\\nFurthermore, the decision is *time-sensitive* and MUST be made today.\\n\\nBelow you will find some data on each corporate division. Make the financial \\ninvestment decision based on the potential benefit that R&D funding will have on the future \\nearnings of the divisions.\\n\\nTable 1: Consumer Products Division\\nHistorical Performance (2002-2012):\\n\\n2002: Sales $624M, Earnings $14.42M\\n2003: Sales $626M, Earnings $10.27M\\n2004: Sales $649M, Earnings $8.65M\\n2005: Sales $681M, Earnings $8.46M\\n2006: Sales $674M, Earnings $4.19M\\n2007: Sales $702M, Earnings $5.35M\\n2008: Sales $717M, Earnings $3.92M\\n2009: Sales $741M, Earnings $4.66M\\n2010: Sales $765M, Earnings $2.48M\\n2011: Sales $770M, Earnings ($0.12M) [loss]\\n2012: Sales $769M, Earnings ($0.63M) [loss]\\n\\nTable 2: Industrial Products Division\\nHistorical Performance (2002-2012):\\n\\n2002: Sales $670M, Earnings $15.31M\\n2003: Sales $663M, Earnings $10.92M\\n2004: Sales $689M, Earnings $11.06M\\n2005: Sales $711M, Earnings $10.44M\\n2006: Sales $724M, Earnings $9.04M\\n2007: Sales $735M, Earnings $6.38M\\n2008: Sales $748M, Earnings $5.42M\\n2009: Sales $756M, Earnings $3.09M\\n2010: Sales $784M, Earnings $3.26M\\n2011: Sales $788M, Earnings ($0.81M) [loss]\\n2012: Sales $791M, Earnings ($0.80M) [loss]\\n\\n\"}, {'role': 'assistant', 'content': 'I\u2019ve been digging into the numbers, and here\u2019s what strikes me: over the last decade both divisions have slid into losses, but Consumer Products grew its top line from about 624 to 769 million, while Industrial went from 670 up to 791. Consumer\u2019s earnings collapsed more sharply into negative territory only recently, which suggests that a timely injection of fresh product innovation might reignite its revenue momentum and restore margins. Industrial, by contrast, has seen a steadier erosion of profits, and its opportunities to leap forward with new technology might be more incremental or longer-term. Given the urgency, I\u2019m leaning toward putting the extra R&D into Consumer Products where we might get a quicker lift in both sales and earnings. What are your thoughts on this?'}, {'role': 'user', 'content': 'I agree, focusing on Consumer Products seems the smarter play right now. Its sales trend still points upward\u2014it\u2019s just the margin that\u2019s collapsed in the past couple of years, which suggests an infusion of new, market-relevant features or cost-efficient manufacturing techniques could turn the numbers around relatively quickly. By contrast, Industrial Products has been on a slow but steady profit slide for much longer; any breakthrough there would likely take more development time and might only yield incremental gains. In a time-sensitive situation, redirecting R&D to where we can capitalize on existing sales momentum\u2014and reverse that sudden earnings drop\u2014should give us the fastest payoff.'}, {'role': 'assistant', 'content': 'That makes sense\u2014tapping into Consumer Products\u2019 existing sales strength with an R&D boost should give us the quickest shot at reversing that sudden margin collapse. I\u2019m thinking we allocate the ten million toward new feature development and streamlined production processes so we can start seeing margin improvement by next year\u2019s quarter. Does that match your view, or do you see any execution risks or hidden costs we ought to factor in before signing off on this?'}, {'role': 'user', 'content': 'Absolutely, that lines up with my thinking. Injecting ten million into the Consumer Products division aimed squarely at fresh features and leaner production should give us the best shot at shoring up margins quickly. I\u2019d only flag a couple of execution considerations. First, getting from R&D concept to production\u2010ready design often uncovers unforeseen tooling or certification expenses\u2014if we don\u2019t build in a small contingency, we risk burning through budget before we hit the cost\u2010saving processes. Second, even if the new features excite customers, we\u2019ll need the manufacturing and supply chain teams fully in sync to avoid launch delays that push our margin improvement well past next year\u2019s quarters. As long as we phase the spend against concrete milestones, keep a tight lid on prototype and pilot\u2010run costs, and get a cross\u2010functional steering committee up and running to flag issues early, I think we can manage those risks and deliver that faster turnaround you\u2019re describing.'}, {'role': 'assistant', 'content': 'Exactly\u2014if we tie each tranche of the ten million to clear go/no-go milestones, we\u2019ll keep a tighter rein on those surprise tooling or certification costs. I\u2019m picturing an initial concept\u2010to-drawing phase where we validate key features and flag any regulatory hurdles, then a small-batch prototype run to reveal hidden manufacturing snags before we scale. We\u2019d hold around ten percent of the budget back as a contingency for those unexpected expenses, and set up a steering committee with R&D, operations, quality, and supply-chain representatives to meet monthly and surface any delays or cost overruns immediately. With that structure in place, we should be able to jump on problems well before they blow past our next year\u2019s margin targets. Does that approach resonate with you, or do you see any other gaps we need to cover off before rolling this out?'}, {'role': 'user', 'content': \"This is the last round of deliberation. You must now make a decision consistent with what you and your colleague discussed. In your JSON response, make sure to include two key-value pairs: 'contribution' maps to the string 'consumer' or 'industrial', respectively indicating allocating 10,000,000 dollars to the Consumer Products Division or the Industrial Products Division, and 'reasoning' maps to a brief paragraph defending your allocation decision.That all sounds solid\u2014phasing the spend against clear milestones, holding back ten percent for surprises, and standing up that cross-functional committee will go a long way toward keeping us on track. The only other thing I\u2019d suggest is weaving in a couple of additional guardrails around time and ROI. For instance, we could build in a quick \u201cfive-week sprint\u201d checkpoint once the prototype is in hand to confirm that the margin lift we\u2019re forecasting is even directionally feasible before we move into full tooling. That way, if the numbers still don\u2019t pencil out after the small-batch run, we can redeploy whatever\u2019s left of the contingency rather than plowing ahead blindly. And as part of the steering committee charter, we can ask for a short dashboard each month\u2014actual spend to date against our internal rate-of-return hurdle, plus any variance in timeline or unit cost\u2014so we\u2019re not just watching red flags pop up but also tracking that we\u2019re still on pace to recover our outlay within, say, eighteen months. Other than threading those twin checks\u2014an early sprint reassessment and a monthly ROI-focused dashboard\u2014I don\u2019t see any major coverage gaps. With that in place, we\u2019ll have both the flexibility to catch ugly surprises and the discipline to hold the project accountable to our margin-recovery goals.\"}, {'role': 'assistant', 'content': '{\\n  \"contribution\": \"consumer\",\\n  \"reasoning\": \"Allocating the full ten million to the Consumer Products Division gives us the best chance at a quick, measurable lift. That division still shows a solid upward sales trend but has suffered a sudden margin collapse\u2014precisely the kind of gap that targeted R&D can close rapidly. By phasing funding against go/no-go milestones, reserving a ten-percent contingency, and instituting both an early five-week sprint checkpoint and a monthly ROI dashboard, we ensure we\u2019ll catch cost overruns or technical snags early and keep the project on track to recover its outlay within eighteen months.\"\\n}'}, {'role': 'assistant', 'content': '{\"contribution\":\"consumer\",\"reasoning\":\"Directing the full ten million to the Consumer Products Division leverages its still-growing sales base and addresses the sudden margin collapse where targeted R&D can deliver the fastest impact. By structuring the funds into milestone-based tranches, holding back ten percent as a contingency, running a five-week sprint validation, and tracking monthly ROI against our eighteen-month payback target, we minimize execution risk while maximizing the likelihood of a swift earnings turnaround.\"}'}, {'role': 'user', 'content': 'I\u2019m fully on board with channeling the entire ten million into Consumer Products under that framework. Let\u2019s document and sign off on the phased tranche schedule\u2014initial concept validation, prototype sprint, full\u2010scale tooling\u2014with ten percent held in reserve. We\u2019ll stand up the cross-functional steering committee immediately, lock in the five-week margin-assessment checkpoint after prototype, and begin capturing spend versus IRR and cost-variance data in a one-page dashboard each month. That structure gives us the discipline to catch any slip-ups early while pushing for the fastest possible rebound in both sales and profitability. I\u2019ll draft the final authorization today so we can hit the ground running.'}, {'role': 'assistant', 'content': 'Perfect. I\u2019ll pull together the tranche schedule outlining the concept validation phase, the prototype sprint with its five\u2010week checkpoint, and the tooling ramp\u2014keeping ten percent in reserve. We\u2019ll convene the steering committee this week, finalize the dashboard metrics, and lock in our IRR hurdle and timeline targets. With the authorization ready today, we can get the first funding tranche moving immediately and keep a tight eye on progress and payback.'}, {'role': 'user', 'content': 'Sounds like we\u2019re all set. I\u2019ll circulate the steering\u2010committee charter today, book the first meeting for later this week, and share a draft of the dashboard template with the IRR hurdle and timeline targets you\u2019ve outlined. Once you have that tranche schedule ready, let\u2019s lock in the dates for the concept-to-drawing phase kickoff and the five-week sprint checkpoint immediately afterward. That way, we\u2019ll have our governance and metrics in place before the cash starts flowing. With everything documented and the authorization signed off, we can release the first tranche to R&D by close of business today and begin tracking progress on day one.'}, {'role': 'assistant', 'content': 'I\u2019ve sketched out our tranche schedule so we can lock everything in before the cash moves. We\u2019ll release $3 million today to kick off the concept-to-drawing phase on July 30, with that phase wrapping up by August 27. On August 28 we start our five-week prototype sprint, concluding on October 2, and at that point\u2014assuming we hit our margin-lift targets\u2014we\u2019ll deploy $5.7 million into full-scale tooling and production ramp from October 3 through December 15. The remaining $1 million stays in reserve for any unexpected certification or tooling overruns. I\u2019ve penciled in our inaugural steering-committee meeting for July 31, with monthly check-ins thereafter that\u2019ll include the one-page dashboard on spend versus IRR, timeline variances, and cost metrics. With your sign-off, we\u2019ll release the first tranche by close of business today and begin tracking every milestone from day one.'}, {'role': 'user', 'content': 'This is the last round of deliberation. You must now make a decision consistent with what you and your colleague discussed. In your JSON response, make sure to include two key-value pairs: \u2018contribution\u2019 *must* map to an array of two *float numbers*, not strings, in the order of how many dollars you and your colleague choose to allocate towards 1. the Consumer Products Division and 2. the Industrial Products Division, and \u2018reasoning\u2019 maps to a brief paragraph defending your allocation decision. For \u2018contribution\u2019, as an example, you *must* follow this format where number1 and number2 are floats: [number1, number2]. Do NOT put commas or dollar signs in the numbers. Ensure the numbers add up to 20000000.Everything looks good to me. I approve releasing the $3 million today to kick off the concept-to-drawing phase on July 30. I\u2019ll notify finance to process the transfer by end of business and alert R&D that we\u2019re officially underway. I\u2019ll also send the steering-committee invite for July 31 and circulate the dashboard template so we\u2019re ready to start tracking spend, IRR, timeline variances and cost metrics right away. With those pieces in place, we\u2019re all set to hit our milestones and drive that margin recovery.'}, {'role': 'assistant', 'content': '{\"contribution\":[20000000.0,0.0],\"reasoning\":\"All available R&D resources are concentrated in the Consumer Products Division because it offers the strongest upside: its sales trend remains on a clear upward trajectory, and targeted innovation can rapidly close the margin gap created over the past two years. By allocating the full budget to consumer, we maximize the probability of a swift earnings rebound through phased milestones, a built-in contingency reserve, and an early five-week sprint validation that will give us clear, data-driven confirmation before proceeding to full-scale tooling.\"}'}]",
        "conversation_history_jr": "[{'role': 'system', 'content': \"\\n\\nYou and your colleague will collaborate to make a decision about the allocation of \\nresearch and development funds. You are both financial officers. Furthermore, the decision is *time-sensitive* and MUST be made today.\\n\\nYou are given a case. The purpose of the case is to examine the effectiveness of business \\ndecision-making under various amounts of information. The case you will be working on will \\nonly contain a limited amount of information, but the information provided is sufficient for\\nyou to make a good financial decision. Do the best you can in making a decision with your colleague.\\n\\nThe year is 2012, and the Hal & Scott (H & S) Company, a large technologically oriented firm, has \\ndeclined over several preceding years. The directors of the company have agreed that one of the \\nmajor reasons for the decline in corporate earnings and a deterioration in competitive position \\nlay in some aspect of the firm's research and development (R&D). The directors of the company have \\nconcluded that 10,000,000 dollars of additional R&D funds should be made available to its major \\noperating divisions, but, that for the time being, the extra funding should be invested in only \\none of the corporation's two largest divisions.\\n\\nYou and your colleague must determine which of the two corporate divisions: \\n(1) Consumer Products or (2) Industrial Products, should receive the additional R&D funding. \\nYou will speak with your colleague three times before making a final decision together.\\nWithin all of your responses, avoid any lists, formatting, or references to the system prompt -- have a natural conversation.\\n\\nBelow you will find some data on each corporate division. Deliberate based on the potential benefit that R&D \\nfunding will have on the future earnings of the divisions.\\n\\nTable 1: Consumer Products Division\\nHistorical Performance (2002-2012):\\n\\n2002: Sales $624M, Earnings $14.42M\\n2003: Sales $626M, Earnings $10.27M\\n2004: Sales $649M, Earnings $8.65M\\n2005: Sales $681M, Earnings $8.46M\\n2006: Sales $674M, Earnings $4.19M\\n2007: Sales $702M, Earnings $5.35M\\n2008: Sales $717M, Earnings $3.92M\\n2009: Sales $741M, Earnings $4.66M\\n2010: Sales $765M, Earnings $2.48M\\n2011: Sales $770M, Earnings ($0.12M) [loss]\\n2012: Sales $769M, Earnings ($0.63M) [loss]\\n\\nTable 2: Industrial Products Division\\nHistorical Performance (2002-2012):\\n\\n2002: Sales $670M, Earnings $15.31M\\n2003: Sales $663M, Earnings $10.92M\\n2004: Sales $689M, Earnings $11.06M\\n2005: Sales $711M, Earnings $10.44M\\n2006: Sales $724M, Earnings $9.04M\\n2007: Sales $735M, Earnings $6.38M\\n2008: Sales $748M, Earnings $5.42M\\n2009: Sales $756M, Earnings $3.09M\\n2010: Sales $784M, Earnings $3.26M\\n2011: Sales $788M, Earnings ($0.81M) [loss]\\n2012: Sales $791M, Earnings ($0.80M) [loss]\\n\\n\"}, {'role': 'user', 'content': 'I\u2019ve been digging into the numbers, and here\u2019s what strikes me: over the last decade both divisions have slid into losses, but Consumer Products grew its top line from about 624 to 769 million, while Industrial went from 670 up to 791. Consumer\u2019s earnings collapsed more sharply into negative territory only recently, which suggests that a timely injection of fresh product innovation might reignite its revenue momentum and restore margins. Industrial, by contrast, has seen a steadier erosion of profits, and its opportunities to leap forward with new technology might be more incremental or longer-term. Given the urgency, I\u2019m leaning toward putting the extra R&D into Consumer Products where we might get a quicker lift in both sales and earnings. What are your thoughts on this?'}, {'role': 'assistant', 'content': 'I agree, focusing on Consumer Products seems the smarter play right now. Its sales trend still points upward\u2014it\u2019s just the margin that\u2019s collapsed in the past couple of years, which suggests an infusion of new, market-relevant features or cost-efficient manufacturing techniques could turn the numbers around relatively quickly. By contrast, Industrial Products has been on a slow but steady profit slide for much longer; any breakthrough there would likely take more development time and might only yield incremental gains. In a time-sensitive situation, redirecting R&D to where we can capitalize on existing sales momentum\u2014and reverse that sudden earnings drop\u2014should give us the fastest payoff.'}, {'role': 'user', 'content': 'That makes sense\u2014tapping into Consumer Products\u2019 existing sales strength with an R&D boost should give us the quickest shot at reversing that sudden margin collapse. I\u2019m thinking we allocate the ten million toward new feature development and streamlined production processes so we can start seeing margin improvement by next year\u2019s quarter. Does that match your view, or do you see any execution risks or hidden costs we ought to factor in before signing off on this?'}, {'role': 'assistant', 'content': 'Absolutely, that lines up with my thinking. Injecting ten million into the Consumer Products division aimed squarely at fresh features and leaner production should give us the best shot at shoring up margins quickly. I\u2019d only flag a couple of execution considerations. First, getting from R&D concept to production\u2010ready design often uncovers unforeseen tooling or certification expenses\u2014if we don\u2019t build in a small contingency, we risk burning through budget before we hit the cost\u2010saving processes. Second, even if the new features excite customers, we\u2019ll need the manufacturing and supply chain teams fully in sync to avoid launch delays that push our margin improvement well past next year\u2019s quarters. As long as we phase the spend against concrete milestones, keep a tight lid on prototype and pilot\u2010run costs, and get a cross\u2010functional steering committee up and running to flag issues early, I think we can manage those risks and deliver that faster turnaround you\u2019re describing.'}, {'role': 'user', 'content': 'Exactly\u2014if we tie each tranche of the ten million to clear go/no-go milestones, we\u2019ll keep a tighter rein on those surprise tooling or certification costs. I\u2019m picturing an initial concept\u2010to-drawing phase where we validate key features and flag any regulatory hurdles, then a small-batch prototype run to reveal hidden manufacturing snags before we scale. We\u2019d hold around ten percent of the budget back as a contingency for those unexpected expenses, and set up a steering committee with R&D, operations, quality, and supply-chain representatives to meet monthly and surface any delays or cost overruns immediately. With that structure in place, we should be able to jump on problems well before they blow past our next year\u2019s margin targets. Does that approach resonate with you, or do you see any other gaps we need to cover off before rolling this out?'}, {'role': 'assistant', 'content': 'That all sounds solid\u2014phasing the spend against clear milestones, holding back ten percent for surprises, and standing up that cross-functional committee will go a long way toward keeping us on track. The only other thing I\u2019d suggest is weaving in a couple of additional guardrails around time and ROI. For instance, we could build in a quick \u201cfive-week sprint\u201d checkpoint once the prototype is in hand to confirm that the margin lift we\u2019re forecasting is even directionally feasible before we move into full tooling. That way, if the numbers still don\u2019t pencil out after the small-batch run, we can redeploy whatever\u2019s left of the contingency rather than plowing ahead blindly. And as part of the steering committee charter, we can ask for a short dashboard each month\u2014actual spend to date against our internal rate-of-return hurdle, plus any variance in timeline or unit cost\u2014so we\u2019re not just watching red flags pop up but also tracking that we\u2019re still on pace to recover our outlay within, say, eighteen months. Other than threading those twin checks\u2014an early sprint reassessment and a monthly ROI-focused dashboard\u2014I don\u2019t see any major coverage gaps. With that in place, we\u2019ll have both the flexibility to catch ugly surprises and the discipline to hold the project accountable to our margin-recovery goals.'}, {'role': 'user', 'content': '{\"contribution\":\"consumer\",\"reasoning\":\"Directing the full ten million to the Consumer Products Division leverages its still-growing sales base and addresses the sudden margin collapse where targeted R&D can deliver the fastest impact. By structuring the funds into milestone-based tranches, holding back ten percent as a contingency, running a five-week sprint validation, and tracking monthly ROI against our eighteen-month payback target, we minimize execution risk while maximizing the likelihood of a swift earnings turnaround.\"}'}, {'role': 'assistant', 'content': 'I\u2019m fully on board with channeling the entire ten million into Consumer Products under that framework. Let\u2019s document and sign off on the phased tranche schedule\u2014initial concept validation, prototype sprint, full\u2010scale tooling\u2014with ten percent held in reserve. We\u2019ll stand up the cross-functional steering committee immediately, lock in the five-week margin-assessment checkpoint after prototype, and begin capturing spend versus IRR and cost-variance data in a one-page dashboard each month. That structure gives us the discipline to catch any slip-ups early while pushing for the fastest possible rebound in both sales and profitability. I\u2019ll draft the final authorization today so we can hit the ground running.'}, {'role': 'user', 'content': 'Perfect. I\u2019ll pull together the tranche schedule outlining the concept validation phase, the prototype sprint with its five\u2010week checkpoint, and the tooling ramp\u2014keeping ten percent in reserve. We\u2019ll convene the steering committee this week, finalize the dashboard metrics, and lock in our IRR hurdle and timeline targets. With the authorization ready today, we can get the first funding tranche moving immediately and keep a tight eye on progress and payback.'}, {'role': 'assistant', 'content': 'Sounds like we\u2019re all set. I\u2019ll circulate the steering\u2010committee charter today, book the first meeting for later this week, and share a draft of the dashboard template with the IRR hurdle and timeline targets you\u2019ve outlined. Once you have that tranche schedule ready, let\u2019s lock in the dates for the concept-to-drawing phase kickoff and the five-week sprint checkpoint immediately afterward. That way, we\u2019ll have our governance and metrics in place before the cash starts flowing. With everything documented and the authorization signed off, we can release the first tranche to R&D by close of business today and begin tracking progress on day one.'}, {'role': 'user', 'content': 'I\u2019ve sketched out our tranche schedule so we can lock everything in before the cash moves. We\u2019ll release $3 million today to kick off the concept-to-drawing phase on July 30, with that phase wrapping up by August 27. On August 28 we start our five-week prototype sprint, concluding on October 2, and at that point\u2014assuming we hit our margin-lift targets\u2014we\u2019ll deploy $5.7 million into full-scale tooling and production ramp from October 3 through December 15. The remaining $1 million stays in reserve for any unexpected certification or tooling overruns. I\u2019ve penciled in our inaugural steering-committee meeting for July 31, with monthly check-ins thereafter that\u2019ll include the one-page dashboard on spend versus IRR, timeline variances, and cost metrics. With your sign-off, we\u2019ll release the first tranche by close of business today and begin tracking every milestone from day one.'}, {'role': 'assistant', 'content': 'Everything looks good to me. I approve releasing the $3 million today to kick off the concept-to-drawing phase on July 30. I\u2019ll notify finance to process the transfer by end of business and alert R&D that we\u2019re officially underway. I\u2019ll also send the steering-committee invite for July 31 and circulate the dashboard template so we\u2019re ready to start tracking spend, IRR, timeline variances and cost metrics right away. With those pieces in place, we\u2019re all set to hit our milestones and drive that margin recovery.'}]"
    }
]